Related Experiment Video

Updated: Jul 31, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Current and emerging therapies for type 2 diabetes

Jing Xu1

  • 1BioMinerva Group, 11553 Hadar Drive, San Diego, CA 92126, USA. jxu4@san.rr.com

Idrugs : the Investigational Drugs Journal
|March 11, 2004
PubMed

Insights

Type 2 diabetes impacts millions globally. While current treatments delay progression, preventing pre-diabetes is key. Public awareness of diabetes risk factors and symptoms is vital for control.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Public Health

Background:

  • Diabetes mellitus affects over 150 million people worldwide.
  • Type 2 diabetes accounts for approximately 90% of all diabetes cases.
  • Effective management and prevention strategies are crucial due to the disease's prevalence.

Purpose of the Study:

  • To review current and emerging therapies for type 2 diabetes.
  • To examine the impact of these therapies on disease etiology and progression.
  • To highlight the importance of prevention for pre-diabetic individuals.

Main Methods:

  • Literature review of existing and novel type 2 diabetes treatments.
  • Analysis of therapeutic effects on the underlying causes and advancement of the disease.
  • Examination of preventative measures and public health awareness strategies.

Main Results:

  • Current therapies primarily delay the progression of type 2 diabetes.
  • Preventing the onset of diabetes in pre-diabetic individuals is feasible.
  • Public awareness campaigns are essential for diabetes prevention and management.

Conclusions:

  • While complete reversal is challenging, delaying type 2 diabetes progression is achievable with current therapies.
  • Preventing the development of type 2 diabetes offers a significant public health benefit.
  • Increased public knowledge of diabetes risk factors and symptoms is critical for effective control and prevention efforts.

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.